Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents
Open Access
- 23 April 2016
- journal article
- review article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (30) , 48692-48731
Abstract
Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agentsKeywords
This publication has 321 references indexed in Scilit:
- Lessons from next-generation sequencing analysis in hematological malignanciesBlood Cancer Journal, 2013
- Lipid raft-mediated Akt signaling as a therapeutic target in mantle cell lymphomaBlood Cancer Journal, 2013
- Composite mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: a clinicopathologic and molecular studyHuman Pathology, 2013
- Proteasome inhibitors in mantle cell lymphomaBest Practice & Research Clinical Haematology, 2012
- Molecular Targeted Approaches in Mantle Cell LymphomaSeminars in Hematology, 2011
- Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphomaThe Journal of Antibiotics, 2011
- BAFF inhibition: A new class of drugs for the treatment of autoimmunityExperimental Cell Research, 2011
- Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 studyThe Lancet Oncology, 2011
- Antiproliferative and proapoptotic activity of GUT-70 mediated through potent inhibition of Hsp90 in mantle cell lymphomaBritish Journal of Cancer, 2010
- Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphomaCancer, 2010